Skip to main content

5 Result(s)

within Jacobus J. Bosch Remove this filter

and

  1. Article

    Open Access

    Students’ guide to documentation in clinical trials

    In the wake of the coronavirus disease 2019 (COVID-19) pandemic, support in clinical trials by students of human medicine and related disciplines has become of even greater importance than in pre-pandemic time...

    Johannes Heck, Ann-Kathrin Rath, Katrin Wons… in European Journal of Clinical Pharmacology (2022)

    Download PDF (490 KB) View Article

  2. Article

    Open Access

    Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2

    We used the RNActive® technology platform (CureVac N.V., Tübingen, Germany) to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding for a stabilized form of SARS-CoV‑2 spike (S) protein...

    Peter G. Kremsner, Philipp Mann MD, Arne Kroidl… in Wiener klinische Wochenschrift (2021)

    Download PDF (514 KB) View Article

  3. No Access

    Article

    Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells

    We are exploring cell-based vaccines as a treatment for the 50% of patients with large primary uveal melanomas who develop lethal metastatic disease. MHC II uveal melanoma vaccines are MHC class I+ uveal melanoma...

    Jacobus J. Bosch, Uzoma K. Iheagwara, Sarah Reid… in Cancer Immunology, Immunotherapy (2010)

  4. No Access

    Article

    Lung cancer patients’ CD4+ T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells

    Advanced non-small cell lung cancer (NSCLC) remains an incurable disease. Immunotherapies that activate patients’ T cells against resident tumor cells are being developed; however, these approaches may not be ...

    Minu K. Srivastava, Jacobus J. Bosch, James A. Thompson… in Cancer Immunology, Immunotherapy (2008)

  5. No Access

    Article

    The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes

    Activation of tumor-reactive T lymphocytes is a promising approach for the prevention and treatment of patients with metastatic cancers. Strategies that activate CD8+ T cells are particularly promising because of...

    James A. Thompson, Minu K. Srivastava, Jacobus J. Bosch… in Cancer Immunology, Immunotherapy (2008)